Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-311 in mild Alzheimer's Disease
NCT02551809Phase 2Completed
- Sponsor
- Vaxxinity
- Start
- Oct 2015
- Primary completion
- Aug 2018
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UB-311 in Alzheimer's disease (AD) (3 arms), sponsored by Vaxxinity. Primary endpoints: Tolerability and Safety Profile of UB-311 Assessed Via Recording of Number of Participants With Adverse Events at 78 weeks and Immunogenicity of UB-311 at 78 weeks. Started Oct 2015; status: completed.
02
Drugs
UB-311
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02551809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551809.